In Conversation with Heather Morehouse Ettinger
New York partner Dr. Heather Ettinger was the subject of a July 14 BioTuesdays article, titled appropriately, “In conversation with Heather Morehouse Ettinger.”
In the piece, Heather talks about everything from the America Invents Act, its biggest impact – inter partes review, the court decision that has impacted her life sciences practice the most to what the next hot topic in life sciences IP will be. “’Product hopping’ or ‘product switching’ antitrust claims,” she stated to the latter. “What was traditionally considered to be standard pharmaceutical life cycle management, where for example immediate release formulations of approved drugs are replaced with extended release formulations, is being attacked on antitrust grounds. I think this is going to be a big issue over the next couple of years.”